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Fc receptors for IgG (FcγR) link innate and 
adaptive immunity by their ability to mediate 
eff  ector cell interactions with antigen–antibody 
(Ab) complexes and Ab-coated target cells 
(1, 2). Mouse eff  ector cells express four dif-
ferent FcγR classes: FcγRI (CD64), FcγRIIB 
(CD32), FcγRIII (CD16), and the recently 
described FcγRIV (also termed FcRL3 and 
CD16-2; references 3–5). FcγRIV is expressed 
by myeloid cells and shares 63% amino acid se-
quence identity with FcγRIII (CD16) in hu-
mans (3–5). FcγRI, FcγRIII, and FcγRIV are 
hetero-oligomeric receptors in which the re-
spective ligand-binding α chains generate stim-
ulatory signals through ITAM sequences found 
within a shared common γ chain subunit (Fc 
receptor common γ chain [FcRγ]) that is re-
quired for FcγR assembly. FcRγ chain ITAM 
sequences are essential to initiate or augment 
eff  ector cell responses such as Ab-dependent 
cellular cytotoxicity (ADCC) and phagocyto-
sis (1, 2). High-affi   nity FcγRI preferentially 
binds monomeric IgG2a, whereas FcγRIII 
binds with low affi   nity to IgG2a/IgG1/IgG2b, 
and FcγRIV binds with intermediate affi   nity 
to IgG2a and IgG2b in vitro (1). In contrast 
to stimulatory FcγRs, FcγRIIB contains ITIM 
sequences that inhibit eff  ector cell responses. 
Coexpression of both activation and inhibi-
tory FcγRs on macrophages, neutrophils, and 
mast cells appropriately balances protective and 
pathogenic innate eff  ector responses after IgG 
immune complex engagement (6). Imbalances 
between stimulatory and inhibitory FcγR func-
tions can also contribute to autoimmunity in 
humans and mice (7).
Chimeric or radiolabeled mAb therapies 
directed against CD20 expressed by mature B 
lymphocytes represent an eff  ective treatment 
for non-Hodgkin’s lymphoma (8–12) and may 
treat rheumatoid arthritis, idiopathic thrombo-
cytopenic purpura, hemolytic anemia, and other 
immune-mediated diseases (13, 14). Mouse 
anti–mouse CD20 mAbs (15) have   provided a 
Antibody isotype-specifi  c engagement of Fcγ 
receptors regulates B lymphocyte depletion 
during CD20 immunotherapy
Yasuhito Hamaguchi,1 Yan Xiu,1 Kazuhiro Komura,1 Falk Nimmerjahn,2 
and Thomas F. Tedder1
1Department of Immunology, Duke University Medical Center, Durham, NC 27710
2Laboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY 10021
CD20 monoclonal antibody (mAb) immunotherapy is effective for lymphoma and auto-
immune disease. In a mouse model of immunotherapy using mouse anti–mouse CD20 mAbs, 
the innate monocyte network depletes B cells through immunoglobulin (Ig)G Fc receptor 
(Fc𝗄R)-dependent pathways with a hierarchy of IgG2a/c>IgG1/IgG2b>IgG3. To understand 
the molecular basis for these CD20 mAb subclass differences, B cell depletion was assessed 
in mice defi  cient or blocked for stimulatory Fc𝗄RI, Fc𝗄RIII, Fc𝗄RIV, or FcR common 𝗄 chain, 
or inhibitory Fc𝗄RIIB. IgG1 CD20 mAbs induced B cell depletion through preferential, if not 
exclusive, interactions with low-affi  nity Fc𝗄RIII. IgG2b CD20 mAbs interacted preferentially 
with intermediate affi  nity Fc𝗄RIV. The potency of IgG2a/c CD20 mAbs resulted from 
Fc𝗄RIV interactions, with potential contributions from high-affi  nity Fc𝗄RI. Regardless, 
Fc𝗄RIV could mediate IgG2a/b/c CD20 mAb–induced depletion in the absence of Fc𝗄RI 
and Fc𝗄RIII. In contrast, inhibitory Fc𝗄RIIB defi  ciency signifi  cantly increased CD20 mAb–
induced B cell depletion by enhancing monocyte function. Although Fc𝗄R-dependent 
pathways regulated B cell depletion from lymphoid tissues, both Fc𝗄R-dependent 
and -independent pathways contributed to mature bone marrow and circulating B cell 
clearance by CD20 mAbs. Thus, isotype-specifi  c mAb interactions with distinct Fc𝗄Rs 
contribute signifi  cantly to the effectiveness of CD20 mAbs in vivo, which may have 
  important clinical implications for CD20 and other mAb-based therapies.
CORRESPONDENCE
Thomas F. Tedder:
thomas.tedder@duke.edu
Abbreviations used: Ab, anti-
body; ADCC, Ab-dependent 
cellular cytotoxicity; FcγR, 
Fc receptor for IgG; FcRγ, 
Fc receptor common γ chain.744  FCγR-MEDIATED B CELL DEPLETION IN CD20 IMMUNOTHERAPY | Hamaguchi et al.
preclinical model for CD20 mAb immunotherapy amena-
ble to mechanistic studies and genetic manipulation. In this 
model, CD20 mAbs engage the innate mononuclear phago-
cytic network and deplete blood and tissue B cells through 
FcγR-dependent and complement-independent mechanisms 
(16, 17). These anti–mouse CD20 mAbs thereby provide ef-
fective tools for understanding how innate eff  ector mecha-
nisms function in vivo. B cell depletion is CD20 mAb isotype 
specifi  c, with IgG2a/c mAbs exhibiting the greatest potency 
(16). An IgG2c CD20 mAb eff  ectively depletes B cells in 
both FcγRI−/− and FcγRIII−/− mice, but is not eff  ective 
in FcRγ−/− mice (16). The recently identifi  ed functional 
characteristics of FcγRIV may explain the FcγR dependence 
but FcγRI and FcγRIII independence of this IgG2c CD20 
mAb in vivo. These Ab isotype–specifi  c eff  ects are clini-
cally important because the antitumor eff  ect of CD20 mAbs 
in humans depends in part on FcγR-dependent immune 
  activation (18), and a chimeric CD20 mAb of an isotype 
diff  erent than that used clinically does not deplete normal 
B cells in nonhuman primates (19). Moreover, human FcγRIIa 
and FcγRIIIa polymorphisms correlate with the effi   ciency 
of B cell and tumor depletion during CD20 mAb therapy 
in lupus and lymphoma patients (20–22). Thus, a molecular 
understanding of the diff  erent roles of each FcγR during 
B cell depletion is essential for mechanism-based predictions 
of biological outcomes for mAb-based immunotherapies.
To identify molecular mechanisms of innate eff  ector 
cell function in vivo, B cell depletion was assessed in mice 
with FcγRI, FcγRIIB, FcγRIII, FcγRIV, or FcRγ block-
ade or defi  ciency using IgG1, IgG2a/c, and IgG2b isotype 
mAbs that bind mouse CD20. We show that IgG1 CD20 
mAb–induced B cell depletion predominantly, if not exclu-
sively, required FcγRIII expression, whereas IgG2a/c and 
IgG2b CD20 mAb–induced B cell depletion was primarily 
performed through FcγRIV with potential FcγRI inter-
actions. In contrast, FcγRIIB expression inhibited CD20 
mAb–induced B cell depletion in vivo. These fi  ndings pro-
vide new insight into the therapeutic as well as potentially 
pathogenic innate eff   ector mechanisms that can mediate 
ADCC in vivo.
Figure 1.  IgG1, IgG2c, and IgG2b CD20 mAb reactivity with B cells 
in wild-type, FcR𝗄−/−, Fc𝗄RI−/−, Fc𝗄RIIB−/−, and Fc𝗄RIII−/− mice. 
CD20 mAb reactivity with enriched spleen B cells as assessed by indirect 
immunofl  uorescence staining with fl  ow cytometry analysis. Fluorescence 
intensities of CD20+ cells stained with CD20 (solid line) or isotype-
matched control (dashed line) mAbs shown on a four-decade log scale.JEM VOL. 203, March 20, 2006  745
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RESULTS
Isotype-specifi  c CD20 mAb depletion of B cells in vivo
Six CD20 mAbs representative of each IgG isotype eff  ec-
tive for B cell depletion, IgG1 (MB20-1 and MB20-14), 
IgG2a (MB20-16), IgG2c (MB20-11), and IgG2b (MB20-
7 and MB20-18), were assessed for their ability to deplete 
blood and tissue B cells in vivo in a dose-dependent man-
ner 7 d after mAb administration. Although the MB20-18 
mAb reacted with B cells at the highest density among CD20 
mAbs, each individual CD20 mAb reacted similarly with 
blood, spleen, and lymph node B220+ cells from wild-type, 
FcRγ−/−, FcγRI−/−, FcγRIIB−/−, and FcγRIII−/− mice 
(Fig. 1 and not depicted).
When mAb depletion of tissue B cells in wild-type mice 
was assessed over a range of mAb concentrations (1–250 μg/
mouse), a hierarchy of depletion effi   ciencies for bone mar-
row, blood, spleen, and lymph node B cells was observed with 
MB20-11 (IgG2c) displaying the greatest activity (Fig. 2 A 
and Table I). Similar, if not identical, results were obtained us-
ing the IgG2a (MB20-16) mAb (not depicted), suggesting that 
IgG2a/c mAbs were similar in their abilities to bind FcγR. 
The IgG1 (MB20-1 and MB20-14) and IgG2b (MB20-18) 
mAbs depleted B cells similarly when used at low mAb con-
centrations, although the IgG1 mAbs depleted signifi  cantly 
more spleen B cells than the MB20-18 mAb when used at 
250-μg doses (Fig. 2 A, Table I, and not depicted) as described 
previously (16). Each of the mAbs (MB20-11, MB20-16, 
MB20-1, MB20-14, and MB20-18) was saturating at >25-μg 
doses, which represented the maximal levels of depletion pos-
sible, even with higher mAb doses over a 7-d treatment pe-
riod (Fig. 2 A and Table I). The MB20-7 mAb did not deplete 
B cells effi   ciently at any dose (not depicted). The high reac-
tivity of MB20-18 with B cells (Fig. 1) may explain why this 
mAb depleted 84–94% of wild-type spleen B cells when used 
Figure 2.  Isotype-specifi  c CD20 mAb utilization of Fc𝗄RI, Fc𝗄RIIB, 
Fc𝗄RIII, and FcR𝗄 during B cell depletion. (A) MB20-1 (IgG1), MB20-
11 (IgG2c), or MB20-18 (IgG2b) CD20 mAb depletion of B cells in wild-
type, FcγRI−/−, FcγRIIB−/−, and FcγRIII−/− mice. Bone marrow (mature 
IgM+B220hi), blood (B220+), spleen (mature CD24+CD21+B220+), and 
peripheral lymph node (B220+) B cell numbers were determined for 7 d 
after mAb treatment at the indicated doses. Values (±SEM) represent the 
percentage of B cells present in mAb-treated mice (two or more mice per 
value) relative to control mAb–treated littermates (250 μg; two or more 
mice per value). Signifi  cant differences between sample means of mice 
treated with MB20-1 and MB20-11 mAbs (*, P < 0.05; **, P < 0.01) or 
MB20-1 and MB20-18 mAbs (†, P < 0.05; ††, P < 0.01) are indicated. 
(B) Comparison of B cell depletion for each mAb isotype in FcRγ−/−, 
FcγRI−/−, and FcγRIII−/− mice as shown in A. Signifi  cant differences 
between sample means of wild-type mice and each mutant strain are 
indicated: †, P < 0.05; ††, P < 0.01.746  FCγR-MEDIATED B CELL DEPLETION IN CD20 IMMUNOTHERAPY | Hamaguchi et al.
Table I. Tissue B cell subset-specifi  c depletion with CD20 mAbsa
Tissue B subseta CD20 mAb Isotype B cells (%) remaining relative to control mAb treatmentb
Wild-type FcRγ−/− FcγRI−/− FcγRIII−/− FcγRIIB−/−
Bone marrow pro/pre IgG1 140 149 172c 67d 84
IgG2c 130 99 119 122 96
IgG2b 141 61d 127 107 74d
immature IgG1 46 87 173c,e 87 83
IgG2c 75 87 120e 114 31
IgG2b 69 53 163c 75 76
mature IgG1 17f 82e 23f 40f 19f
IgG2c 5f 82e 4f 3f 6f
IgG2b 8f 54c,e 28f,d 9f 10f
Blood B220+ IgG1 2f 41f,e 4f 34f,e 2f
IgG2c <1f 70c,e 1f 1f <1f
IgG2b 4f 43c,e 8f 7f 6f
Spleen mature IgG1 1f 140f,e 7f 109e 2f
IgG2c 2f 182f,e 3f 2f 2f
IgG2b 16f 75e 25f,e 33f 19f
T1 IgG1 28f 88d 7f 34c 11f,d
IgG2c 5f 42f,e 6f 4f 2f
IgG2b 14f 55e 13f 14f 13f
T2 IgG1 <1f 79e 5f 100e 3f
IgG2c 1f 99e 2f 1f 6f,d
IgG2b 6f 48f,e 9f 13f,e 4f
Peripheral LN B220+ IgG1 27f 163e 6f 104e 3f
IgG2c 6f 97e 6f 1f 2f
IgG2b 35f 72d 15f 19f 6f,d
Peritoneum B220+ IgG1 115 156 109 85 76
IgG2c 52c 107d 52f 71c 73
IgG2b 113 75 60 60 83
B-1a IgG1 147 125 79 54 63d
IgG2c 68 127 73 68 78
IgG2b 131 78 67 65 53d
B-1b IgG1 106 89 123 97 72
IgG2c 66 135 68 69 75
IgG2b 107 65 40 93 81
B2 IgG1 60 179 89 89 34f
IgG2c 33c 93d 60c 77 43f
IgG2b 50 74 76 94 50
aB cell subsets were: bone marrow pro–/pre–B (IgM−B220lo), immature B (IgM+B220lo), and mature B (IgM+B220hi); spleen mature (CD24+CD21+B220+), 
T1 (CD24hiCD21−B220+), and T2 (CD24hiCD21+B220+); and peritoneal B-1a (CD5+CD11b+IgMhiB220lo), B-1b (CD5−CD11b+IgMhiB220lo), and B2 (CD5−IgMloB220hi). LN, lymph node.
bPooled values indicate the percentages of B cells in CD20 mAb–treated mice (50–250 μg; IgG1 MB20-1, IgG2c MB20-11, and IgG2b MB20-18) relative to control 
mAb–treated littermates (50–250 μg; n ≥ 4 per value). Signifi  cant differences between mean B cell numbers in CD20 mAb–treated mice compared with control 
mAb–treated littermates are indicated:
cP < 0.05 and
fp < 0.01.
Signifi  cant differences between mean percentages of B cells in each mutant mouse strain after CD20 mAb treatment relative to percentages obtained in wild type 
mice are indicated:
dP < 0.05 and
eP < 0.01.
at 250 μg/mouse (Table I), whereas the MB20-7 and two 
other IgG2b CD20 mAbs only depleted 3–36% of B cells (16). 
The IgG1, IgG2a/c, and IgG2b CD20 mAbs signifi  cantly de-
pleted mature bone marrow and circulating B cells, with T1, 
T2, and mature B cells depleted from the spleen and lymph 
nodes, whereas peritoneal B cells were only signifi  cantly de-
pleted   using IgG2a/c CD20 mAbs in wild-type mice (Table I 
and not depicted). Isotype-matched control mAbs had no 
measurable eff  ects on B cell numbers (not depicted). Two dif-
ferent IgG3 CD20 mAbs (MB20-3 and MB20-13) failed to JEM VOL. 203, March 20, 2006  747
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deplete signifi  cant numbers of tissue B cells when used at any 
concentration, as described previously (16). As in wild-type 
mice, the IgG2c (MB20-11) mAb was the most eff  ective for B 
cell depletion in FcγRI−/−, FcγRIIB−/−, or FcγRIII−/− mice 
(Fig. 2 A and Table I). Isotype-matched control mAbs did not 
aff  ect B cell numbers in FcRγ−/−, FcγRI−/− FcγRIIB−/−, or 
FcγRIII−/− mice (not depicted). Thus, IgG1, IgG2a/c, IgG2b, 
and IgG3 CD20 mAbs infl  uenced B cell numbers through 
isotype- and FcγR-specifi  c mechanisms.
Roles for activating Fc𝗄Rs in B cell depletion
The roles of individual FcγRs in B cell depletion by CD20 
mAbs were assessed by directly comparing B cell depletion in 
mice defi  cient in FcRγ, FcγRI, or FcγRIII. IgG1, IgG2a/c, 
and IgG2b CD20 mAbs each required FcRγ expression for 
the majority of bone marrow, blood, and tissue B cell deple-
tion (Fig. 2 B, Table I, and not depicted), as described previ-
ously (16). Uniquely, FcγRIII expression was required for 
MB20-1 (IgG1) mAb treatment but had no eff  ect on IgG2a/c 
or IgG2b CD20 mAb–induced B cell depletion. Two inde-
pendent FcγRIII−/− mouse lines (23, 24) generated identi-
cal results (not depicted). In contrast, FcγRI defi  ciency had 
much less dramatic eff  ects on CD20 mAb–induced B cell 
depletion. Thus, IgG1 CD20 mAbs preferentially, if not ex-
clusively, used FcγRIII for B cell depletion in vivo.
The role of the newly identifi  ed FcγRIV molecule in 
B cell depletion by IgG2b (100 μg MB20-18) and IgG2c (25 μg 
MB20-11) CD20 mAbs was assessed using FcγRI−/−/
FcγRIII−/− mice, where only FcγRIV is expressed. At 
these doses, both the IgG2b and IgG2c CD20 mAbs de-
pleted signifi  cant numbers of blood and spleen B cells in 
both FcγRI−/−/FcγRIII−/− and wild-type mice (Fig. 3 A). 
Combined FcγRI/FcγRIII defi   ciencies inhibited IgG2b 
CD20 mAb–induced B cell depletion when compared with 
wild-type mice, suggesting that FcγRI and/or FcγRIII may 
contribute to IgG2b/c CD20 mAb depletion in addition to 
FcγRIV. Regardless, FcγRIV mediated eff  ective IgG2b and 
IgG2c CD20 mAb–induced B cell depletion in the absence 
of both FcγRI and FcγRIII expression. The role of FcγRIV 
in B cell depletion by IgG2b CD20 mAbs was further verifi  ed 
Figure 3.  Fc𝗄RIV mediates B cell depletion by IgG2b (MB20-18) 
and IgG2c (MB20-11) CD20 mAbs. (A) Blood, spleen, and lymph node 
B cell depletion in FcγRI−/−/FcγRIII−/− and wild-type mice treated with 
MB20-18 (100 μg; gray circles/bars), MB20-11 (25 μg; fi  lled circles/
bars), or control IgG2a (100 μg; open circles/bars) mAbs. Values (±SEM) 
indicate mean circulating B cell numbers (per ml) before (time 0) and 
1 h or 1, 2, 4, or 7 d after mAb treatment (three or more mice per value). 
Mean (±SEM) spleen or lymph node B cell numbers were determined 
7 d after mAb treatment (three or more mice per group). (B) B cell 
  depletion in wild-type mice treated with IgG2b control mAb (100 μg; 
open circles/bars) or MB20-18 mAb (100 μg; fi  lled circles/bars) in com-
bination with FcγRIV-blocking 9E9 (200 μg; gray circles/bars) or control 
(CTL; 200 μg; fi  lled circles/bars) mAb on day 0 as indicated. (C) B cell 
depletion in mAb-treated wild-type or FcγRI−/− mice. Mice were treated 
with IgG2a control mAb (2.5 or 25 μg; open circles/bars) or MB20-11 
mAb (2.5 or 25 μg; fi  lled circles/bars) in combination with FcγRIV-
blocking 9E9 mAb (200 μg; gray circles/bars) or control (CTL; 200 μg; 
fi  lled circles/bars) mAb on day 0 as indicated. In A–C, signifi  cant differ-
ences between mean results for control and CD20 mAb–treated mice 
are indicated (†, P < 0.05; ††, P < 0.01), with numbers indicating the 
mean relative percentages of B220+ lymphocytes in MB20-11/MB20-18 
mAb–treated mice compared with control mAb–treated littermates.748  FCγR-MEDIATED B CELL DEPLETION IN CD20 IMMUNOTHERAPY | Hamaguchi et al.
in wild-type mice using the recently described FcγRIV func-
tion-blocking mAb, 9E9 (5). The MB20-18 (IgG2b) mAb at
100 μg depleted between 50 and 90% of blood and tissue 
B cells, but this was signifi  cantly attenuated or eliminated when
FcγRIV function was blocked using the 9E9 mAb (Fig. 3 B). 
These results suggest that FcγRIV preferentially mediates 
IgG2b CD20 mAb–induced B cell depletion.
In wild-type mice, the IgG2c MB20-11 mAb at 2.5 μg/
mouse depleted most circulating (>95%) B cells by day 7 and 
signifi  cantly reduced spleen and lymph node B cell numbers 
(Fig. 3 C). Blocking FcγRIV activity with the 9E9 mAb in 
wild-type mice treated with low-dose MB20-11 mAb inhib-
ited lymph node B cell depletion but did not signifi  cantly re-
duce blood and spleen B cell depletion. However, blocking 
FcγRIV function in FcγRI−/− mice signifi  cantly aff  ected the 
ability of IgG2c CD20 mAbs to deplete B cells in vivo. Spe-
cifi  cally, 60% of circulating B cells were depleted in FcγRI−/− 
mice treated with low-dose MB20-11 mAb (2.5 μg), whereas 
B cell depletion was not observed when FcγRIV function 
was also blocked. Circulating, splenic, and lymph node B 
cells in FcγRI−/− mice were also signifi  cantly depleted by 
MB20-11 mAb at a 25-μg dose, but B cell depletion was sig-
nifi  cantly reduced when FcγRIV function was also blocked. 
Thus, FcγRIV contributed substantially to IgG2c CD20 mAb–
induced B cell depletion, but FcγRI expression may also fa-
cilitate B cell depletion by the MB20-11 mAb, particularly 
when CD20 mAb doses are limiting.
Role for Fc𝗄RIIB in B cell depletion
As an inhibitory receptor expressed by monocytes and 
B cells, FcγRIIB defi  ciency could aff  ect B cell depletion. 
Therefore, FcγRIIB−/− mice were treated with IgG1, 
IgG2a/c, and IgG2b CD20 mAbs over a range of concentra-
tions. Splenic and lymph node B cell depletion by IgG1 
CD20 mAb treatment was signifi   cantly augmented in 
FcγRIIB−/− mice when used at 50–100-μg doses (Fig. 4 and 
not depicted). Lymph node B cell depletion by IgG2a/c and 
IgG2b CD20 mAbs was also signifi   cantly enhanced by 
FcγRIIB defi  ciency (Fig. 4 and not depicted). The MB20-1 
(IgG1) and MB20-18 (IgG2b) mAbs depleted >90% of 
Figure 4.  Fc𝗄RIIB defi  ciency augments CD20 mAb–induced B cell 
depletion. Bone marrow (mature IgM+B220hi), blood (B220+), spleen 
(mature CD24+CD21+B220+), and lymph node (B220+) B cell numbers 
were determined for wild-type and FcγRIIB−/− mice 7 d after MB20-1, 
MB20-11, or MB20-18 mAb treatment at the indicated doses. Values 
(±SEM) represent the percentage of B cells present in mAb-treated mice 
(two or more mice per value) relative to control mAb–treated littermates 
(250 μg; two or more mice per value), with signifi  cant differences be-
tween sample means of wild-type mice and each mutant strain indicated: 
†, P < 0.05; ††, P < 0.01.JEM VOL. 203, March 20, 2006  749
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lymph node B cells when used at ≥25-μg doses in 
FcγRIIB−/− mice, whereas these mAbs maximally depleted 
70–80% of B cells when used at higher concentrations in 
wild-type littermates. The MB20-11 IgG2c mAb depleted 
90% of lymph node B cells at 10-fold lower mAb concentra-
tions in FcγRIIB−/− mice. As a result, lymph node B cell 
depletion in FcγRIIB−/− mice was as effi   cient as spleen 
B cell depletion in CD20 mAb–treated wild-type mice. 
FcγRIIB defi  ciency did not signifi  cantly enhance the degree 
of bone marrow or blood B cell clearance. Within the peri-
toneal cavity, FcγRIIB defi  ciency did not enhance the   degree 
of peritoneal B-1a and B-1b cell clearance after CD20 mAb 
treatments but did facilitate IgG1 CD20 mAb–induced de-
pletion of conventional B2 cells (Table I). Thus, expression 
Figure 5.  Fc𝗄RIIB−/− B cells resist CD20 mAb–induced depletion in 
wild-type mice. (A) Flow cytometry analysis of FcγRIIB expression (thick 
lines) by B cell subsets from FcRγ−/− mice. Spleen B cell subsets were 
identifi  ed as mature (CD24+CD21+B220+), T1 (CD24hiCD21−B220+), and 
T2 (CD24hiCD21+B220+). Peritoneal cavity B cell subsets were identifi  ed as 
B-1a (CD5+CD11b+IgMhiB220lo), B-1b (CD5−CD11b+IgMhiB220lo), and B2 
(CD5−IgMloB220hi). Solid lines indicate 2.4G2 mAb staining, and dotted 
lines indicate isotype-matched control mAb reactivity. (B) Flow cytometry 
analysis of CFSE-labeled B220+ and B220− lymphocytes from wild-type 
and FcγRIIB−/− mice on day 1 indicating gates used to assess frequencies 
of adoptively transferred CFSE+ wild-type and FcγRIIB−/− cells. Spleno-
cytes from wild-type (WT) and FcγRIIB−/− (RIIB−/−) mice were labeled 
with CFSE at different intensities, mixed, and transferred into wild-type 
littermates 1 d before treatment with MB20-11 or control mAb (25 μg). 
After 1 d, blood, spleen, and peripheral lymph node lymphocytes were 
isolated and assessed for B220 expression. Bar graphs indicate the relative 
ratios of cells from wild-type and FcγRIIB−/− donors within the CFSE-
labeled B220+ and B220− lymphocyte populations. Results represent 
those obtained with three or more mouse pairs, with signifi  cant differ-
ences between sample means (±SEM) indicated: *, P < 0.05; **, P < 0.01.750  FCγR-MEDIATED B CELL DEPLETION IN CD20 IMMUNOTHERAPY | Hamaguchi et al.
of this inhibitory receptor signifi  cantly reduced the eff  ective-
ness of B cell depletion by CD20 mAbs in vivo.
Role for B cell Fc𝗄RIIB in B cell depletion
Spleen T1, T2, and mature B cells and peritoneal cavity B-1a, 
B-1b, and B2 cells uniformly expressed FcγRIIB, although 
there was variability in FcγRIIB expression densities between 
individual spleen and peritoneal cavity B cell subsets (Fig. 5 A). 
It was therefore assessed whether augmented B cell depletion 
in FcγRIIB−/− mice resulted from a change in B cell or 
monocyte FcγRIIB expression. FcγRIIB−/− splenocytes and 
control splenocytes from wild-type mice were diff  erentially 
labeled with CFSE, mixed together in equal proportions, and 
adoptively transferred into recipient mice 1 d before CD20 
mAb treatment. 1 d after CD20 mAb treatment, the relative 
frequencies of CFSE-labeled B220+ and B220− lymphocytes 
in the blood, spleen, and lymph nodes were quantifi  ed by 
fl  ow cytometry (Fig. 5 B). The relative frequency of wild-
type B220+ lymphocytes in the blood, spleen, and lymph 
nodes was more signifi  cantly reduced in MB20-11 CD20 
mAb–treated mice when compared with the frequency of 
FcγRIIB−/− B220+ lymphocytes. Control mAb treatment 
did not aff  ect the relative ratios of B220+ FcγRIIB−/− and 
B220+ wild-type lymphocytes in these adoptive transfer ex-
periments. Likewise, CD20 mAb treatment did not aff  ect the 
relative ratios of B220− FcγRIIB−/− and B220− wild-type 
lymphocytes. Thus, FcγRIIB defi  ciency reduced the relative 
rate of B cell depletion compared with wild-type B cells, al-
though FcγRIIB−/− B cells were eff  ectively depleted after 7 d 
of CD20 mAb treatment (Table I).
Role for Fc𝗄Rs in B cell subset depletion
Subtle eff  ects of FcγR defi  ciencies on B cell subset depletion 
were also observed (Table I). For example, the number of 
pro–/pre–B cells present in bone marrow after IgG1 mAb 
treatment was signifi   cantly increased in FcγRI−/− mice. 
Similar eff  ects on immature bone marrow B cells in FcγRI−/− 
mice were observed after IgG1 and IgG2b mAb treatments. 
MB20-11 mAb treatment also increased spleen B cell num-
bers in FcRγ−/− mice compared with control mAb–treated 
littermates, predominantly due to increased numbers of im-
mature B cells (not depicted). Thus, alterations in FcγR ex-
pression signifi  cantly aff  ected the dynamics of B cell subset 
depletion after CD20 mAb treatment.
DISCUSSION
The extent of B cell depletion induced by CD20 mAbs cor-
related closely with IgG isotype, with IgG2a/c mAbs being 
the most eff  ective and IgG3 mAbs having modest eff  ects in 
vivo (Fig. 1 and Table I; reference 16). Although our previ-
ous studies suggested reciprocal roles for FcγRI or FcγRIII 
in CD20 mAb–induced depletion of B cells (16), the current 
studies demonstrate that diff  erential FcγR utilization explains 
diff   erences in eff   ectiveness between CD20 mAb isotypes. 
IgG1 CD20 mAb–induced B cell depletion was predomi-
nantly, if not exclusively, performed through low-affi   nity 
FcγRIII (Fig. 2 and Table I). Preferential IgG1 interactions 
with FcγRIII for phagocytosis of IgG1-coated erythrocytes 
or immune complexes, and in animal models of experimental 
autoimmune hemolytic anemia and passive cutaneous ana-
phylaxis, have been demonstrated previously (25, 26). In 
contrast, IgG2b and IgG2a/c CD20 mAb–induced B cell de-
pletion was primarily performed through intermediate affi   n-
ity FcγRIV, although high-affi   nity FcγRI interactions may 
also contribute to this process (Figs. 2 and 3). Importantly, 
FcγRIV mediated eff  ective B cell deletion by both IgG2a/c 
and IgG2b CD20 mAbs in the absence of both FcγRI and 
FcγRIII (Fig. 3 A). Because simultaneous blockade of 
FcγRIV function and FcγRI expression prevented B cell de-
pletion by IgG2b and IgG2a/c CD20 mAbs, FcγRIII may 
have minimal interactions with these mAb isotypes. Although 
mouse IgG3 is reported to bind FcγRI (27), IgG3 CD20 
mAbs had little eff  ect in vivo (16). Thus, monocyte expres-
sion of either FcγRIV or FcγRIII is suffi   cient for B cell de-
pletion when mAbs of the correct isotypes are considered. 
These fi  ndings explain why IgG2a/c CD20 mAb therapy was 
eff  ective in both FcγRI−/− and FcγRIII−/− mice, but not in 
FcRγ−/− mice (Fig. 2 B and Table I; reference 16). Thereby, 
each IgG isotype demonstrated preferential specifi  city for dif-
ferent stimulatory FcγRs.
The importance of mAb isotype in immunotherapy has 
long been appreciated, particularly for mouse IgG2a mAbs 
(28–32). Like IgG2a/c CD20 mAbs for B cell depletion 
(Fig. 2 A and not depicted), IgG2a anti-erythrocyte mAbs 
induce more severe FcγR-dependent hemolytic anemia 
than IgG2b mAbs (33). However, because FcγRIV binds 
IgG2a and IgG2b mAbs with similar affi   nities in vitro (5), it 
was surprising that IgG2a/c CD20 mAbs depleted B cells at 
least 10-fold better than the IgG2b MB20-18 CD20 mAb in 
vivo (Fig. 1; reference 16). Moreover, the MB20-18 mAb 
primarily used in the current studies is the most potent of 
four IgG2b CD20 mAbs assessed for B cell depletion (16). 
It is therefore possible that engagement of both FcγRIV 
and FcγRI by IgG2a/c CD20 mAbs explains their higher 
potency in vivo (Fig. 3 A). High-affi   nity FcγRI may par-
ticipate in some IgG2a-mediated eff  ects in certain experi-
mental model systems, although FcγRI may play a minor 
role in vivo because administered mAbs must compete with 
intrinsic circulating Abs for high-affi   nity FcγRI interactions 
(34). Determining the precise contribution of FcγRI to 
IgG2a/b/c CD20 mAb eff  ectiveness in vivo will require the 
generation and characterization of FcγRIV-defi  cient mice. 
Alternatively, mAb isotype–  specifi  c structural features may 
explain the potency of IgG2a isotype CD20 mAbs in vivo. 
For example, IgG2a/c and IgG2b CD20 mAbs may bind cell 
surface CD20 diff  erently or have diff  erent eff  ects on target 
antigen/Ab densities during CD20 mAb–induced ADCC, 
or allow the effi   cient clustering of CD20 on the surface of 
B cells. IgG2a/c isotype switching may also select for CD20 
mAbs with high intrinsic potencies, high mAb affi   nities, or 
unique fi  ne specifi  cities for CD20. Regardless, the greater 
activity of IgG2a/c CD20 mAbs in vivo was not explained JEM VOL. 203, March 20, 2006  751
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by unique eff   ects on ADCC through FcγRIIB negative 
  regulation (Fig. 4).
CD20 mAb–induced B cell depletion was reduced by 
monocyte expression of FcγRIIB in vivo, with FcγRIIB 
  defi  ciency also revealing tissue-specifi  c eff  ects on B cells (Fig. 
4 and Table I). FcγRIIB defi  ciency signifi  cantly enhanced 
lymph node B cell depletion by IgG1, IgG2c, and IgG2b 
CD20 mAbs, whereas FcγRIIB defi  ciency only enhanced 
IgG1 CD20 mAb–induced spleen B cell depletion when 
used at higher mAb doses. Lymph node B cell depletion was 
less effi   cient than spleen B cell depletion at equivalent CD20 
mAb doses, but lymph node and spleen B cell depletion were 
similar in the absence of FcγRIIB expression. Likewise, 
FcγRIIB defi  ciency did not signifi  cantly enhance B-1a or 
B-1b cell depletion from the peritoneal cavity (Table I), pop-
ulations of B cells that are more resistant to CD20 mAb–
induced depletion than peritoneal B2 cells (17). Therefore, 
circumventing the negative regulatory role of FcγRIIB may 
be most advantageous during suboptimal mAb dosing or for 
B cell depletion within lymph nodes. Consistent with this, 
FcγRIIB deletion enhances the cytotoxicity of human Fc 
region–chimerized or -humanized mAbs targeting tumors in 
vivo, including rituximab targeting of human lymphoma 
cells in nude mice (18). Surprisingly, however, FcγRIIB−/− 
B cells were also more resistant to CD20 mAb–induced 
depletion than wild-type B cells (Fig. 5). FcγRIIB−/− B cell 
resistance to CD20 mAb treatment did not result from 
reduced CD20 expression (Fig. 1), and peritoneal B-1a or 
B-1b cell resistance to CD20 mAb–induced depletion did 
not result from low FcγRIIB expression (Fig. 5 A). None-
theless, no signifi  cant relationship has been found between 
FcγRIIB protein expression on diff  use large B cell lympho-
mas and the prognosis of patients or their outcome after 
rituximab  therapy (35). Thus, circumventing monocyte 
inhibitory FcγRII function in vivo could result in more 
  eff  ective immunotherapies, but this may be infl  uenced by 
tissue-specifi   c factors including the localization of target 
B cells or ADCC eff  ector cells.
Although tissue B cell clearance was FcRγ dependent, 
circulating B cell clearance was mediated through both 
FcRγ-dependent and -independent pathways. In the absence 
of FcRγ expression, 30–57% of circulating B cells were 
cleared by IgG1, IgG2a/c, and IgG2b CD20 mAbs on day 7 
(Fig. 1, Table I, and not depicted). Similar results were ob-
tained for mature bone marrow B cells, which include the 
recirculating B cell pool. Most IgG2b and IgG3 anti–mouse 
CD20 mAbs also deplete blood B cells but have modest, if 
any, eff  ects on spleen B cells (16). This demonstrates that 
blood and circulating bone marrow B cells share common 
properties that allow their clearance without operable ADCC. 
Rapid blood B cell depletion is also observed in patients after 
CD20 mAb infusions (36–39). However, the current results 
suggest that blood B cell clearance may not necessarily cor-
relate with tissue B cell clearance. Consistent with this, 
  human FcγRIIIa polymorphisms are not predictive of patient 
responses in chronic lymphocytic leukemia, which most 
commonly involves blood and marrow (40). Thus, although 
FcγR-mediated ADCC remains a primary mechanism for 
B cell depletion in vivo, FcγR-independent pathways also 
infl  uence the clearance of circulating B cells.
Collectively, these results indicate that the most impor-
tant factors infl  uencing CD20 mAb effi   cacy in vivo are mAb 
isotype and capacity to interact with FcγRs. These results 
also further support previous fi  ndings whereby Ab isotypes 
exhibit functional hierarchies in their relative abilities to en-
gage diff  erent FcγRs in vivo. The current immunotherapy 
studies also correlate with models of adaptive immunity 
where IgG2a Abs are most effi   cient in providing optimal or 
substantial protection during bacterial, viral, and fungal in-
fections (41–45). Thus, the intricate innate eff  ector pathways 
used for B cell depletion in the current studies may have been 
selected evolutionarily for potency. The current observations 
also corroborate studies in lupus and lymphoma patients 
showing that human FcγRIIa and FcγRIIIa polymorphisms 
correlate with the effi   ciency of tumor and B cell depletion 
using a chimeric human IgG1 CD20 mAb (20–22). That 
mouse FcγRIV is most structurally similar to human FcγRIII 
(3–5) further implicates the importance of this receptor in 
human B cell depletion after CD20 mAb treatment. Under-
standing whether human Ab isotypes exhibit a functional 
  hierarchy in their relative abilities to engage diff  erent FcγRs 
in vivo will be critical for better manipulating FcγR function 
during immunotherapy or ameliorating the consequences of 
pathogenic autoantibodies. The current studies also indicate 
that it may be important to consider disease- and tissue-
specifi  c targeting eff  ects when manipulating FcγR   expression 
or function for therapeutic benefi   t. Because therapeutic 
  andpathogenic Abs are likely to share many common 
  pathways and FcγR-  dependent processes, a further under-
standing of the molecular complexities of FcγR function and 
signaling in vivo are essential to fully harness the potent 
  stimulatory and inhibitory functions of this receptor system 
in treating human disease.
MATERIALS AND METHODS
Abs and immunofl  uorescence analysis. Mouse CD20–specifi  c mouse 
mAbs were as described previously (15). Hamster anti–mouse FcγRIV mAb, 
9E9, was as described previously (5, 46). Other mAbs included: B220 mAb 
RA3-6B2 (provided by R. Coff  man, DNAX Corp., Palo Alto, CA); Thy1.2 
mAb (Caltag); and CD1d (1B1), CD5 (53-7.3), CD11b (M1/70), CD16/32 
(2.4G2), CD21 (7G6), and CD24 (M1/69) mAbs (BD Biosciences). Isotype-
specifi  c and anti-Ig or anti-IgM Abs were from SouthernBiotech.
Single-cell suspensions of bone marrow (bilateral femurs), spleen, and 
peripheral lymph node (paired axillary and inguinal) lymphocytes were gen-
erated by gentle dissection. To isolate peritoneal cavity leukocytes, 10 ml of 
cold (4°C) PBS was injected into the peritoneum of killed mice followed by 
gentle massage of the abdomen. Viable cells were counted using a hemocyto-
meter, with relative lymphocyte percentages determined by fl  ow cytometry 
analysis. Blood erythrocytes were lysed after immunofl  uorescence staining 
using FACS Lysing Solution (BD Biosciences). Single-cell leukocyte suspen-
sions were stained on ice using predetermined optimal concentrations of 
each Ab for 20–60 min and fi  xed as described previously (47, 48). Cells with 
the light scatter properties of lymphocytes were analyzed by two- to four-
color immuno  fl  uorescence staining with FACScan or FACSCalibur fl  ow 
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using unreactive control mAbs (Caltag) with gates positioned to exclude 
≥98% of the cells.
In some cases, B cell–enriched single-cell lymphocyte preparations were 
generated by incubating 2 × 108 splenocytes with 180 μl anti-Thy1.2 mAb–
coated magnetic beads (Dynal) in 10 ml RPMI 1640 medium containing 5% 
FBS for 30 min at 4°C, followed by T cell removal using a magnet. B cell 
preparations were ≥93% B220+ as determined by immunofl  uorescence 
staining with fl  ow cytometry analysis. The B cell preparations were assessed 
for cell surface CD20 expression as described above, except 106 lymphocytes 
were incubated with each CD20 mAb at 10 μg/ml, washed, and incubated 
with PE-conjugated goat anti–mouse IgG1, IgG2a, or IgG2b isotype– specifi  c 
secondary Ab for immunofl  uorescence staining.
Mice. FcγRI−/− and FcγRIII−/− mice were as described previously (23) 
and crossed to generate FcγRI−/−/FcγRIII−/− mice. C57BL/6, FcγRIIB−/− 
(B6,129S-Fcgr2tm1Rav), and FcγRIII−/− (C57BL/6-Fcgr3tm1Sjv) mice were 
from The Jackson Laboratory. FcRγ-defi  cient mice (FcRγ−/−, B6.129P2-
Fcer1gtm1) were from Taconic Farms. All mice were housed in a specifi  c 
pathogen-free barrier facility and fi  rst used at 2–3 mo of age. All studies were 
approved by the Animal Care and Use Committee of Duke University.
Immunotherapy. Sterile anti–mouse CD20 and isotype control mAbs 
(1–250 μg) in 200 μl PBS were injected through lateral tail veins. Blood 
leukocyte numbers were quantifi  ed by hemocytometer after red cell lysis, 
with blood and tissue B220+ B cell frequencies determined by immunofluo-
rescence staining with flow cytometry analysis as described previously 
(16, 17). Because equivalent results were obtained in mice treated with con-
trol IgG2a, IgG2b, or IgG1 mAbs, the results were pooled in some instances.
Adoptive transfer experiments. Unfractionated splenocytes from 
FcγRIIB−/− and wild-type mice were labeled with 4 and 0.4 μM Vybrant 
CFSE, respectively (Invitrogen), according to the manufacturer’s instruc-
tions. The relative frequency of B220+ cells among CFSE-labeled spleno-
cytes was determined by immunofl  uorescence staining with fl  ow cytometry 
analysis. Subsequently, equal numbers of CFSE-labeled B220+ FcγRIIB−/− 
and wild-type splenocytes (4 × 107) were injected i.v. into wild-type mice 
1 d before i.v. injection of either MB20-11 or control mAbs. After 1 d, cells 
were harvested from each tissue and CFSE-labeled B220+ cells were ana-
lyzed by immunofl  uorescence staining with fl  ow cytometry analysis.
Statistical analysis. All data are shown as means ± SEM. The Student’s 
t test was used to determine the signifi  cance of diff  erences between popula-
tion means.
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